Clinical Assessment and Management of Bipolar Disorder – Summary of RANZCP and BAP Guidelines
Mood disorders are broadly classified as bipolar or depressive disorders.
Bipolar disorder is a chronic recurrent mood disorder where patients can continue to experience subthreshold symptoms, which impact significantly on the quality of life.
Bipolar disorder also poses a significant economic burden. The total costs of Bipolar Disorder I from US data were estimated at $202.1 billion in 2015, corresponding to an average of $81,559 per individual, while the excess costs of Bipolar Disorder I were estimated at $119.8 billion, corresponding to an average of $48,333 per individual. 
We covered the management of unipolar depressive disorders based on RANZCP guidelines in a previous article.
In this review, we will be focusing on clinical management of bipolar disorder based on the main points from RANZCP mood disorder guidelines  and the evidence-based guidelines for treating bipolar disorder from the British Association for Psychopharmacology (BAP). 
This article does not cover management of bipolar disorder in special groups (e.g., perinatal, adolescents) or complex presentations which will be covered in another article.